Trial Profile
A Prospective, International, Multicenter, Open-Label, Non-Controlled Study of Safety and Effectiveness of Palivizumab, in Children at High Risk of Severe Respiratory Syncytial Virus (RSV) Infection in the Russian Federation and the Republic of Belarus
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 15 Mar 2018
Price :
$35
*
At a glance
- Drugs Palivizumab (Primary)
- Indications Respiratory syncytial virus infections
- Focus Therapeutic Use
- Acronyms Synagis Russia
- Sponsors AbbVie
- 28 Jul 2017 Status changed from active, no longer recruiting to completed.
- 31 Jan 2017 Status changed from recruiting to active, no longer recruiting.
- 22 Nov 2016 New trial record